Logo for Grifols SA

Grifols Investor Relations Material

Latest events

Logo for Grifols SA

CMD 2025

Grifols
Logo for Grifols

CMD 2025

27 Feb, 2025
Logo for Grifols

Q4 2024

26 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Grifols SA

Access all reports
Segment Data
Access more data
Revenue by
Business area
Biopharma
Diagnostic
Bio Supplies
Other
Expenses by
Financials
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through the following business segments: Spain and Latin America; the United States and Europe; Asia-Pacific; and Corporate. It offers a range of products, including plasma derivatives in fields such as clinical immunology, infectious diseases, neonatology, hemophilia, and thalassemia; chemotherapeutics for cancer treatment; albumin for surgical oncological indications; and antithrombotic agents for chronic anticoagulation therapy. In addition it offers anti-infective agents used in therapeutic areas such as hematology/oncology, nephrology/diabetes/inflammation/urology-renal transplantation (NRU), and transplantation; bone regeneration products; liquid blood derivatives; diagnostics services; animal blood derivatives; process technology for blood derived products (plasma fractionating); pharmaceutical manufacturing services; artificial blood technologies under development. Further it provides transfusion medicine management services.